KalVista Q3 2020 Earnings Report
Key Takeaways
KalVista Pharmaceuticals reported a revenue of $1.6 million and a net loss of $9.3 million for the third quarter ended January 31, 2020. The company's research and development expenses increased due to ongoing clinical trials and preclinical activities.
Phase 2 clinical trial with KVD900 data expected in the second quarter of this year.
Progress in optimization of KVD824 as a potential oral prophylactic treatment.
Phase 2 trial of KVD001 did not meet its primary endpoint in the overall study population.
KalVista intends to initiate a Phase 2 clinical trial in the second half of 2020 for KVD824.
KalVista
KalVista
KalVista Revenue by Segment
Forward Guidance
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.